ASX shares Echo IQ Ltd (ASX: EIQ) and Sunrise Energy Metals Ltd (ASX: SRL) have enjoyed big returns in 2026.

These ASX shares have risen by over 500% and 125% respectively since the start of the year. 

This huge rise is difficult to ignore for growth investors, and experts have provided updated commentary on these soaring stocks. 

Here is what brokers are saying. 

Volatility expected for Echo IQ

A new report from Bell Potter has included updated guidance on Echo IQ shares. 

It is an ASX-listed medical technology company utilising proprietary, AI-driven software (the EchoSolv platform) to analyse echocardiographic data to aid clinicians in diagnosing serious conditions like aortic stenosis (AS) and left ventricular dysfunction more accurately.

Its share price has stormed higher in 2026 on the back of key US deals and AI development.

A note out of Bell Potter indicates it could experience some volatility moving forward. 

Looking on the positive side, the broker said Echo IQ is making good progress by developing new products and securing long-term funding.

A major positive was partnering with Pro Medicus Ltd (ASX: PME), which gives credibility to its EchoSolv platform.

However, winning new hospital and radiology customers in the US will take time – likely years, not months.

Price target increased 

Bell Potter has increased its price target to $1.75 per share (from $1.65).

The higher valuation reflects the stronger financial position after the capital raise.

However, the broker expects the share price to remain volatile because:

• Revenue growth is expected to be modest over the next two years.
• The company will continue to spend significant cash.
• The share price will likely move based on announcements of new customer wins.

The broker now has a speculative hold recommendation, and based on the updated price target, sees limited share price upside in the next 12 months. 

Last week, these ASX shares closed trading at $1.65. 

Sunrise Metals could keep rising 

Sunrise Metals shares have also rocketed higher in 2026. 

The company is focused on the development and application of ion-exchange technology for extracting valuable metals in the mining industry and for purifying and recycling wastewater.

Positive development updates have helped swing momentum to the positive side for these ASX materials shares. 

According to analyst views via TradingView, this could continue. 

These ASX shares closed last week trading at $17.75 per share. 

The average analyst forecast indicates Sunrise Metals shares could hit $20.00 per share in the next 12 months. 

From last week’s closing price, this indicates a further 12% upside. 

 

 

The post What are experts saying about these red hot ASX shares? appeared first on The Motley Fool Australia.

More reading

• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• 10 of the best ASX shares to buy in FY 2027
• Up more than 550% in a year, why is this ASX biotech charging even higher?
• Buy, hold, sell: Collins Foods, Karoon Energy, and Pro Medicus shares
• Top 3 ASX healthcare stocks to buy today

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have endured a brutal fall over the past year, with investors watching nearly a decade of gains disappear.

The healthcare giant shares are now trading around levels last seen in March 2017, effectively wiping out nine years of share price appreciation. However, there are early signs sentiment may be improving, with CSL shares rallying an impressive 34% over the past month.

Even after that rebound, the stock remains down around 50% over the past 12 months. That raises the big question for investors: can CSL shares eventually recover to last year’s highs above $275?

What do analysts think?

Broker sentiment remains divided. According to TradingView data, 18 analysts have updated their ratings on CSL shares over the past three months. Eight recommend buying the stock or rate it a strong buy, while the remaining 10 have a hold recommendation.

Despite the mixed views, the average price target sits at $141.53, implying upside of around 16% from current levels. The most bullish analyst has a target price of $201.07, suggesting potential upside of roughly 65%.

Among the more optimistic brokers is Morgans, which recently retained its Buy rating and a price target of $147.59. That implies approximately 20% upside, with the broker continuing to back the company’s long-term fundamentals.

Macquarie Group Ltd (ASX: MQG), however, remains more cautious. The broker has a neutral rating and a price target of $114, reflecting uncertainty across CSL’s core plasma and albumin businesses, alongside ongoing competitive pressures.

A quality business facing headwinds

Not long ago, CSL shares were widely regarded as one of the ASX’s most dependable compounders. The company built its reputation on consistent earnings growth, global leadership in plasma-derived therapies, and a long history of delivering strong returns for patient shareholders.

That perception has changed dramatically over the past year. A series of earnings downgrades, leadership changes, and roughly US$5 billion in non-cash impairments linked to the CSL Vifor acquisition have significantly dented investor confidence. Combined, these factors have contributed to the stock’s decline of more than 50%.

Yet despite the sharp sell-off, the underlying business remains highly defensive. CSL is still the world’s second-largest plasma-derived therapies company, operating in an industry with high barriers to entry, stringent regulation, and complex global supply chains. Those competitive advantages are difficult for rivals to replicate.

Can CSL shares recover?

CSL’s latest guidance suggests the business continues to grow, albeit at a slower pace than investors had become accustomed to.

Management expects FY26 revenue of around US$15.2 billion and underlying net profit after tax and amortisation (NPATA) of approximately US$3.1 billion on a constant currency basis.

The biggest challenge remains the US immunoglobulin business within CSL Behring.

While demand continues to grow at a healthy mid-to-high single-digit rate, supply constraints and pricing dynamics have prevented the company from fully capitalising on that demand. That mismatch has weighed on margins and earnings momentum, helping explain why investor sentiment has remained subdued.

Whether CSL shares can eventually reclaim their previous highs will likely depend on management’s ability to improve execution, restore earnings growth, and rebuild market confidence.

For long-term investors, the recent rebound may be encouraging. But with analysts still split and operational challenges yet to fully ease, the path back to $275 is unlikely to be a straight line.

The post After losing half their value, can CSL shares reclaim $275? appeared first on The Motley Fool Australia.

More reading

• ASX healthcare shares have jumped 21% since June. Can the recovery continue?
• 3 ASX shares down at least 50% in FY26
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• How much do I need in superannuation to receive $5,500 per month in passive income?
• 10 of the best ASX shares to buy in FY 2027

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX: WTC) shares showed signs of life last week, finishing 2% higher on Friday and gaining around 7% over the past five trading days.

While the recent rebound has lifted investor sentiment, it’s only a small recovery in the context of the stock’s dramatic decline. WiseTech shares remain down around 20% over the past month. They’ve lost roughly 70% over the past year. This makes the stock one of the biggest losers on the S&P/ASX 200 Index (ASX: XJO) over that period.

The question now is whether this bounce marks the beginning of a sustained recovery, or whether the tech stock is destined to head lower again.

Brokers are overwhelmingly bullish

Despite the steep sell-off, analysts remain surprisingly optimistic. According to TradingView data, 12 of the 15 analysts covering WiseTech rate the stock as either a buy or strong buy. The remaining three recommend holding the shares.

The average 12-month price target stands at $68.37, more than double the current share price of $32.96. The most bullish analyst has a target price of $121.76. This implies potential upside of almost 270% if the company can restore investor confidence.

Bell Potter also remains positive on the outlook for WiseTech shares. Although the broker recently lowered its 12-month price target from $78.75 to $71.75, it retained its buy recommendation. Even after the downgrade, the revised target suggests potential upside of around 118% from current levels.

What caused the sell-off?

Unlike many technology companies that have suffered from slowing revenue growth, WiseTech’s problems haven’t been driven by weakening demand.

Its flagship CargoWise platform remains one of the world’s leading logistics software solutions, serving freight forwarders, customs brokers, and global supply chain operators. The business continues to benefit from long-term trends towards digitalisation and increasingly complex international trade.

Instead, the collapse in WiseTech shares has been driven largely by governance concerns. Questions surrounding founder and executive chairman Richard White first emerged late last year and have continued to overshadow the company’s strong operational performance.

Markets typically place a premium on certainty, particularly when it comes to corporate leadership. As governance concerns dominated headlines, investors became less willing to pay the high valuation that WiseTech had historically commanded.

The result has been a dramatic de-rating, despite the company’s underlying business remaining fundamentally sound.

Did the market overreact?

That is becoming the key debate among investors.

The strength of broker recommendations suggests many believe the sell-off has gone too far. Analysts continue to point to WiseTech’s dominant market position, recurring revenue model and long runway for global growth as reasons to remain optimistic over the long term.

However, governance issues can take time to resolve, and investor confidence is often slow to rebuild. For WiseTech shares to sustain their recent rebound, the market will likely need greater clarity around leadership, governance and execution, alongside continued delivery of strong financial results.

 

The post Can WiseTech shares double from here? Analysts are betting yes appeared first on The Motley Fool Australia.

More reading

• These ASX tech stocks have lost billions. Buy the dip or stay away?
• Does my superannuation affect my Age Pension eligibility?
• 3 ASX shares down at least 50% in FY26
• 9 ASX 200 shares with renewed buy ratings for FY27
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Marc Van Dinther has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.